Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DOCK5 | Q9H7D0 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20103153 | 0.94 | P2RX7 (0.45) | P2RX7GAAMEN1CASP6KMT2A | |
| SCHEMBL18208494 | 0.88 | P2RX7 (0.45) | P2RX7HRH3GAAMEN1CASP6 | |
| SCHEMBL18208520 | 0.85 | P2RX7 (0.44) | P2RX7HRH3DOCK5 | |
| SCHEMBL18208519 | 0.85 | P2RX7 (0.44) | P2RX7HRH3DOCK5 | |
| SCHEMBL18208191 | 0.85 | P2RX7 (0.44) | P2RX7HRH3 | |
| SCHEMBL18208710 | 0.83 | P2RX7 (0.42) | P2RX7HRH3 | |
| SCHEMBL18208556 | 0.83 | P2RX7 (0.42) | P2RX7HRH3 | |
| SCHEMBL18208621 | 0.83 | NPC1 (0.49) | P2RX7GAAMEN1CASP6KMT2A | |
| SCHEMBL20103479 | 0.80 | HSD11B1 (0.51) | HTR1AADRA1AADRA1BALDH1A1 | |
| SCHEMBL18208871 | 0.79 | KMT2A (0.44) | P2RX7HRH3GAAMEN1CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | C1R, C9, C1S | P2RX7 1358/4885HRH3 94/4885GAA 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.